The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
SARS‐CoV‐2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG‐I/MDA‐5–MAVS, TLR3–TRIF, and cGAS–STING signaling pathways
Open accessPublished version of a preprint
Abstract
The suppression of types I and III interferon (IFN) responses by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) contributes to the pathogenesis of coronavirus disease 2019 (COVID‐19). The strategy used by SARS‐CoV‐2 to evade antiviral immunity needs further investigation. Here, we reported that SARS‐CoV‐2 ORF9b inhibited types I and III IFN production by targeting multiple molecules of innate antiviral signaling pathways. SARS‐CoV‐2 ORF9b impaired the induction of types I and III IFNs by Sendai virus and poly (I:C). SARS‐CoV‐2 ORF9b inhibited the activation of types I and III IFNs induced by the components of cytosolic dsRNA‐sensing pathways of RIG‐I/MDA5‐MAVS signaling, including RIG‐I, MDA‐5, MAVS, TBK1, and IKKε, rather than IRF3‐5D, which is the active form of IRF3. SARS‐CoV‐2 ORF9b also suppressed the induction of types I and III IFNs by TRIF and STING, which are the adaptor protein of the endosome RNA‐sensing pathway of TLR3‐TRIF signaling and the adaptor protein of the cytosolic DNA‐sensing pathway of cGAS–STING signaling, respectively. A mechanistic analysis revealed that the SARS‐CoV‐2 ORF9b protein interacted with RIG‐I, MDA‐5, MAVS, TRIF, STING, and TBK1 and impeded the phosphorylation and nuclear translocation of IRF3. In addition, SARS‐CoV‐2 ORF9b facilitated the replication of the vesicular stomatitis virus. Therefore, the results showed that SARS‐CoV‐2 ORF9b negatively regulates antiviral immunity and thus facilitates viral replication. This study contributes to our understanding of the molecular mechanism through which SARS‐CoV‐2 impairs antiviral immunity and provides an essential clue to the pathogenesis of COVID‐19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
The Architecture of SARS-CoV-2 Transcriptome
Kim, D., Lee, J.-Y., Yang, J.-S., Kim, J. W., Kim, V. N., & Chang, H. (2020) · Cell · doi:10.1016/j.cell.2020.04.011 · Cited by 2,123
Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation
Liu, S., Cai, X., Wu, J., Cong, Q., Chen, X., Li, T., Du, F., Ren, J., Wu, Y.-T., Grishin, N. V., et al. (2015) · Science · doi:10.1126/science.aaa2630 · Cited by 1,927 · cited 3×
“The RIG‐I/MDA‐5–MAVS, TLR3–TRIF, and cGAS–STING signaling pathways converge at TBK1/IKKε, which catalyzes IRF3 phosphorylation and the subsequent transcription of types I and III IFNs.(21) Secreted type I and III IFNs bind to their receptors and then activate Janus”
BackgroundShared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
Activation and evasion of type I interferon responses by SARS-CoV-2
Lei, X., Dong, X., Ma, R., Wang, W., Xiao, X., Tian, Z., Wang, C., Wang, Y., Li, L., Ren, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17665-9 · Cited by 980
Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
Park, A., & Iwasaki, A. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.008 · Cited by 909
SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70
Jiang, H.-W., Zhang, H.-N., Meng, Q.-F., Xie, J., Li, Y., Chen, H., Zheng, Y.-X., Wang, X.-N., Qi, H., Zhang, J., et al. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0514-8 · Cited by 351
Self-citationZheng, Y., Zhuang, M.-W., Han, L., Zhang, J., Nan, M.-L., Zhan, P., Kang, D., Liu, X., Gao, C., & Wang, P.-H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00438-7 · Cited by 302
Self-citationInterferon responses in viral pneumonias
Grajales-Reyes, G. E., & Colonna, M. (2020) · Science · doi:10.1126/science.abd2208 · Cited by 46
Research works printed but not linked: 33
- 10.1038/s41586-020-2012-7 · DOI · Paper page
- 10.1016/j.antiviral.2014.06.013 · DOI · Paper page
- 10.1126/sciimmunol.abd1554 · DOI · Paper page
- 10.1016/j.cell.2020.04.026 · DOI · Paper page
- 10.1126/science.abc3545 · DOI · Paper page
- 10.1126/science.abc2061 · DOI · Paper page
- 10.1016/j.coviro.2012.04.004 · DOI · Paper page
- 10.1128/JVI.00016-10 · DOI
- 10.1128/JVI.01199-08 · DOI · Paper page
- 10.1371/journal.ppat.1000636 · DOI
- 10.1007/s13238-014-0026-3 · DOI · Paper page
- 10.1371/journal.pone.0030802 · DOI · Paper page
- 10.1016/j.immuni.2020.05.013 · DOI · Paper page
- 10.1093/cid/ciaa453 · DOI
- 10.1016/S0140-6736(20)31042-4 · DOI · Paper page
- Abigail Vanderheiden PR, 2020, Type I and type III IFN restrict SARS‐CoV‐2 infection of human airway epithelial cultures, bioRxiv
- Lokugamage KG, 2020, SARS‐CoV‐2 is sensitive to type I interferon pretreatment, bioRxiv
- 10.1016/j.celrep.2020.107863 · DOI · Paper page
- 10.1093/nar/gky186 · DOI
- 10.1038/ni.3588 · DOI · Paper page
- 10.1038/ni.3641 · DOI · Paper page
- 10.15252/embr.201845737 · DOI
- Zheng Y, 2020, Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) membrane (M) protein inhibits type I and III interferon production by targeting RIG‐I/MDA‐5 signaling, bioRxiv
- 10.1002/jmv.26139 · DOI · Paper page
- 10.1074/jbc.AC120.013788 · DOI · Paper page
- 10.4049/jimmunol.1303196 · DOI · Paper page
- 10.1080/22221751.2020.1780953 · DOI · Paper page
- 10.1074/jbc.M109.008227 · DOI · Paper page
- 10.1186/s12915-016-0292-z · DOI
- 10.1038/s41590-020-0730-5 · DOI · Paper page
- 10.4049/jimmunol.180.8.5373 · DOI
- 10.1038/srep17554 · DOI
- Zhongji Meng TW, 2020, An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area, medRxiv
Cited by
Lamers, M. M., & Haagmans, B. L. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00713-0 · Cited by 983
Innate immunity: the first line of defense against SARS-CoV-2
Diamond, M. S., & Kanneganti, T.-D. (2022) · Nature Immunology · doi:10.1038/s41590-021-01091-0 · Cited by 618
Karki, R., Lee, S., Mall, R., Pandian, N., Wang, Y., Sharma, B. R., Malireddi, R. S., Yang, D., Trifkovic, S., Steele, J. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo6294 · Cited by 350
Zheng, Y., Zhuang, M.-W., Han, L., Zhang, J., Nan, M.-L., Zhan, P., Kang, D., Liu, X., Gao, C., & Wang, P.-H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00438-7 · Cited by 302
“However, SARS-CoV-2 M protein does not have any effect on TLR3–TRIF signaling activated IFN production; thus, there might be other SARS-CoV-2 proteins such as ORF9b are responsible to the inhibition of IFNs in the lung.(39) Furthermore, Co-IP assays showed that the SARS-CoV-2 M protein interacts with RIG-I, MDA-5, MAV…”
BackgroundSelf-citationSARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19
Gusev, E., Sarapultsev, A., Solomatina, L., & Chereshnev, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031716 · Cited by 281
Metadata
- Authors
- Han, L., Zhuang, M., Deng, J., Zheng, Y., Zhang, J., Nan, M., Zhang, X., Gao, C., & Wang, P.
- Venue
- Journal of Medical Virology
- Publisher
- Wiley
- Published
- 2021-05-09
- Volume
- 93
- Issue
- 9
- Pages
- 5376-5389
- ISSN
- 0146-6615 (ISSN-L)
- 1096-9071
- OpenAlex
- W3158953228
- Cited by
- 245
- References
- 12
- FWCI
- 14.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- Natural Science Foundation of Jiangsu Province (BK20200225)
- National Natural Science Foundation of China (31730026, 81525012, 81930039)
- Natural Science Foundation of Shandong Province (ZR2020QC085)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.